Drug Profile
Research programme: amyloid precursor protein targeted anti-sense oligonucleotides - nLife
Alternative Names: APP anti-sense oligonucleotide - nLifeLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator nLife Therapeutics
- Class Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action Amyloidogenic protein inhibitors; Antisense RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Alzheimer's-disease in Spain (Intranasal)
- 28 Oct 2018 No recent reports of development identified for research development in Alzheimer's-disease in Spain (Intrathecal)
- 01 Sep 2014 Early research in Alzheimer's disease in Spain (Intranasal)